HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment 1

Digestive and Liver Disease

Volumn 39, Issue SUPPL. 1, 2007, Pages

  Zignego, Anna L ^b   Cozzi, Andrea ^a   Carpenedo, Raffaella ^a   Giannini, Carlo ^b   Rosselli, Massimo ^b   Biagioli, Tiziana ^c   Aldinucci, Alessandra ^c   Laffi, Giacomo ^b   Moroni, Flavio ^a  

^a Department of Preclinical and Clinical Pharmacology ^*

^b Department of Internal Medicine

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

5HT; Anxiety; Depression; Indoleamine 2,3 dioxygenase; Kynurenine; Tryptophan metabolism

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; TRYPTOPHAN;

ACCURACY; ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; ENZYME ACTIVITY; ERADICATION THERAPY; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; LIVER INJURY; MACROPHAGE; MALE; MENTAL DISEASE; PSYCHOLOGIC ASSESSMENT; SYMPTOM; TRYPTOPHAN METABOLISM; VOLUNTEER;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON ALFA-2A; KYNURENINE; MACROPHAGES; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; TRYPTOPHAN;

EID: 34948832628     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(07)80021-1     Document Type: Article

References (31)

1. Wolf H. Studies on tryptophan metabolism in man. Scand J Clin Lab Invest 136S (1974) 1-186
2. Moroni F. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur J Pharmacol 375 (1999) 87-100
3. Bender DA. The kynurenine pathway of tryptophan metabolism. In: Stone T. (Ed). Quinolinic Acid and the Kynurenines. (1989), Boca Raton, FL: CRC Press 3-38
4. Hirata H., and Hayaishi O. Studies on indoleamine 2,3-dioxygenase. Superoxide anion as substrate. J Biol Chem 250 (1975) 5960-5966
5. Brown RR. Metabolism and biology of tryptophan. Some clinical implications. Adv Exp Med Biol 398 (1996) 15-25
6. Chiarugi A., Clavani M., Meli E., Traggiai E., and Moroni F. Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages. J Neuroimmunol 120 (2001) 190-198
7. Carlin J., Ozaki Y., Byrne G., Brown R., and Borden E. Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia 45 (1989) 535-541
8. Mellor A., and Munn D. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?. Immunol Today 20 (1999) 469-473
9. Munn D., and Mellor A. IDO and tolerance to tumors. Trends Mol Med 10 (2004) 15-18
10. Heyes M., Saito K., Lackner A., Wiley A., Achim C., and Markey SP. Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques. FASEB J 12 (1998) 881-896
11. Sanni L., Thomas S., Tattam B., Moore D., Chaudhri G., Stocker R., and Hunt NH. Dramatic changes in oxidative tryptophan metabolism along the kynurenine pathway in experimental cerebral and noncerebral malaria. Am J Pathol 152 (1998) 611-619
12. Mann JJ. Neurobiology of suicidal behaviour. Nat Rev Neurosci 4 (2003) 819=828
13. McDonald E., Mann A., and Thomas H. Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers. Lancet 2 (1987) 1175-1178
14. Saito K., Lackner A., Markey S., and Heyes M. Cerebral cortex and lung indoleamine-2,3-dioxygenase activity is increased in type-D retrovirus infected macaques. Brain Res 540 (1991) 353-356
15. Desmet V., Gerber M., Hoofnagle J., Manns M., and Scheuer P. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19 (1994) 1513-1520
16. Zignego A., and Brechot C. Extrahepatic manifestations of HCV infection: facts and controversies. J Hepatol 31 (1999) 369-376
17. Roncone R., Ventura J., Impallomeni M., Falloon I., Morosini P., Chiaravalle E., et al. Reliability of an Italian standardized and expanded Brief Psychiatric Rating Scale (BPRS 4.0) in raters with high vs. low clinical experience. Acta Psychiatr Scand 100 (1999) 229-236
18. Cozzi A., Zignego A., Carpendo R., Biagiotti T., Aldinucci A., Monti M., et al. Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients. J Viral Hepat 13 (2006) 402-408
19. Widner B., Wirleitner B., Baier-Bitterlich G., Weiss G., and Fuchs D. Cellular immune activation, neopterin production, tryptophan degradation and the development of immunodeficiency. Arch Immunol Ther Exp (Warsaw) 48 (2000) 251-258
20. Forton D., Thomas H., Murphy C., Allsop J., Foster G., Main J., et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 35 (2002) 433-439
21. Hilsabeck R., Perry W., and Hassanein T. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 35 (2002) 440-446
22. Kramer L., Bauer E., Funk G., Hofer H., Jessner W., Steindl-Munda P., et al. Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol 37 (2002) 349-354
23. Dwight M., Kowdley K., Russo J., Ciechanowski P., Larson A., and Katon W. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res 49 (2000) 311-317
24. Costa E., and Meek J. Regulation of biosynthesis of catecholamines and serotonin in the CNS. Annu Rev Pharmacol Toxicol 14 (1974) 491-511
25. Veenstra-VanderWeele J., Anderson G., and Cook J.E. Pharmacogenetics and the serotonin system: initial studies and future directions. Eur J Pharmacol 410 (2000) 165-181
26. Munn D., Shafizadeh E., Attwood J., Bondarev I., Pashine A., and Mellor A. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J Exp Med 189 (1999) 1363-1370
27. Saito K., Markey S., and Heyes M. Effects of immune activation on quinolinic acid and kynurenine pathway metabolism in the mouse. Neuroscience 51 (1992) 25-39
28. Fuchs D., Moller A., Reibnegger G., Stockle E., Werner E., and Wachter H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr 3 (1990) 873-876
29. Huang A., Fuchs D., Widner B., Glover C., Henderson D., and Allen-Mersh T. Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 86 (2002) 1691-1696
30. Forrest C., Youd R., Kennedy A., Gould S., Darlington L., and Stone T. Purine, kynurenine, neopterin and lipid peroxidation levels in inflammatory bowel disease. J Biomed Sci 9 (2002) 436-442
31. Bonaccorso S., Marino V., Puzella A., Pasquini M., Biondi M., Artini M., et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 22 (2002) 86-90